国药现代布美他尼注射液获得药品注册证书

Core Viewpoint - The announcement by China National Pharmaceutical Group Modern indicates the approval of Bumetanide injection by the National Medical Products Administration, which expands the company's product offerings in the pharmaceutical market [1] Group 1: Company Announcement - China National Pharmaceutical Group Modern's wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., has received the drug registration certificate for Bumetanide injection [1] - The drug approval number is Guoyao Zhunzi H20256235, signifying regulatory compliance and readiness for market entry [1] Group 2: Drug Indications - Bumetanide injection is primarily indicated for conditions such as edema, hypertension, prevention of acute renal failure, hyperkalemia, hypercalcemia, dilutional hyponatremia, syndrome of inappropriate antidiuretic hormone secretion, and acute drug or toxin poisoning [1]